Cargando…

Pilot study of a ketogenic diet in relapsing-remitting MS

OBJECTIVE: To assess the safety and tolerability of a modified Atkins diet (KD(MAD)), a type of ketogenic diet (KD), in subjects with relapsing MS while exploring potential benefits of KDs in MS. METHODS: Twenty subjects with relapsing MS enrolled into a 6-month, single-arm, open-label study of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brenton, J. Nicholas, Banwell, Brenda, Bergqvist, A.G. Christina, Lehner-Gulotta, Diana, Gampper, Lauren, Leytham, Emily, Coleman, Rachael, Goldman, Myla D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487505/ https://www.ncbi.nlm.nih.gov/pubmed/31089482 http://dx.doi.org/10.1212/NXI.0000000000000565

Ejemplares similares

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
por: Goldman, Myla D., et al.
Publicado: (2020)

Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis
por: Ghassemi, Rezwan, et al.
Publicado: (2014)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Glucocorticoid-associated blood glucose response and MS relapse recovery
por: Goldman, Myla D., et al.
Publicado: (2017)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Ketogenic diet for anxiety disorders: Dietary regimen for relapse prevention?
por: Włodarczyk, A., et al.
Publicado: (2021)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Addressing the targeting range of the ABILHAND-56 in relapsing–remitting multiple sclerosis: A mixed methods psychometric study
por: Cleanthous, Sophie, et al.
Publicado: (2018)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
por: Stellmann, Jan‐Patrick, et al.
Publicado: (2016)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS
por: Sriram, Subramaniam, et al.
Publicado: (2018)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Ketogenic Diet and Epilepsy
por: Ułamek-Kozioł, Marzena, et al.
Publicado: (2019)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

The Therapeutic Role of Ketogenic Diet in Neurological Disorders
por: Pietrzak, Diana, et al.
Publicado: (2022)

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
por: Limmroth, Volker, et al.
Publicado: (2014)

Investigating the relationship between multi-scale perfusion and white matter microstructural integrity in patients with relapsing-remitting MS
por: Sisco, Nicholas J, et al.
Publicado: (2021)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
por: Kearns, Patrick K A, et al.
Publicado: (2022)

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Mapping the Endogenous Ketogenic System Across Ages, Sex and Diets
por: Eap, Brenda, et al.
Publicado: (2021)

Ketogenic diets and physical performance
por: Phinney, Stephen D
Publicado: (2004)

Ketogenic Diet in Epileptic Encephalopathies
por: Sharma, Suvasini, et al.
Publicado: (2013)

An Update on the Ketogenic Diet, 2012
por: Halevy, Ayelet, et al.
Publicado: (2012)

Ketogenic diet in cancer therapy
por: Weber, Daniela D., et al.
Publicado: (2018)

Ketogenic diets: Boon or bane?
por: Shilpa, Joshi, et al.
Publicado: (2018)

Ketogenic Diet in Alzheimer’s Disease
por: Rusek, Marta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cobb1dc138lg1rjdld4pv88mdo